Markers of hyperinflammation

Minerva Anestesiologica

Volumn 68, Issue 4, 2002, Pages 252-256

  Gerlach, M ^a   Gerlach, H ^a,b  

^a Klinik für Anaesthesiologie und Operative Intensivmedizin   (Germany)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

Pathogenesis; Review; Sepsis

Indexed keywords

MARKER; BIOLOGICAL MARKER;

BACTERIAL INFECTION; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATHOGENESIS; REVIEW; SEPSIS; SEPTIC SHOCK; PATHOLOGY;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; SEPSIS; SHOCK, SEPTIC;

EID: 0036545715     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Livingston DH, Mosenthal AC, Deitch EA. Sepsis and multiple organ dysfunction syndrome: A clinical-mechanistic overview. New Horiz 1995;3:257-66.
2. Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995;40:365-94.
3. Byerley LO, Alcock NW, Starnes HF. Sepsis-induced cascade of cytokine mRNA expression: Correlation with metabolic changes. Am J Physiol 1992;261: E728-35.
4. Verhoef G, Boogaerts M. Treatment with granulocyte-macrophage colony-stimulating factor and the adult respiratory distress syndrome. Am J Hematol 1991;36:285-7.
5. Montravers P, Chollet-Martin S, Marmuse JP, Gougerot-Pocidalo MA, Desmonts JM. Lymphatic release of cytokines during acute lung injury complicating severe pancreatitis. Am J Respir Crit Care Med 1995;152:1527-33.
6. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330(6149):662-4.
7. Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB Jr, Murray CK et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990;30(3):279-92.
8. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273(12):934-41.
9. Cohen J, Cartel J. INTERSEPT: an international, multi-center, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24(9):1431-40.
10. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351(9107):929-33.
11. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24(5):733-42.
12. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277(19):1531-8.
13. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995;274(2):172-7.
14. Novogrodsky A, Vanichkin A, Patya M, Gazit A, Osherov N, Levitzki A. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase blockers. Science 1994;264:1319-22.
15. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994;22(1):12-21.
16. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274(8):639-44.
17. Olynyk jk, Matuschak GM, Lechner AJ. Differential production of TNF-α by Kupffer cells after phagocytosis of E. Coli and C. Albicans. Am J Physiol 1994;267:G213-9.
18. Kullberg BJ, van't Wout JW, Poell RJM, van Furth R. Combined effect of fluconazol and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob Agents Chemother 1992;36:1225-9.
19. Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ et al. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant 1996;18(1):93-102.
20. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341(8844):515-8.
21. Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin - a new indicator of the systemic response to severe infections. Infection 1997;25(6):329-34.
22. Jacobs JW, Lund PK, Potts JT Jr, Bell NH, Habener JF. Procalcitonin is a glycoprotein. J Biol Chem 1981;256(6):2803-7.
23. Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984;167(1):93-7.
24. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983;304(5922):129-35.
25. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605-8.
26. Gerard Y, Hober D, Petitjean S, Assicot M, Bohuon C, Mouton Y et al. High serum procalcitonin level in a 4-year-old liver transplant recipient with a disseminated candidiasis. Infection 1995;23(5):310-1.
27. Davis TM, Assicot M, Bohuon C, St John A, Li GQ, Anh TK. Serum procalcitonin concentrations in acute malaria. Trans R Soc Trop Med Hyg 1994;88(6):670-1.
28. Gendrel D, Assicot M, Raymond J, Moulin F, Francoual C, Badoual J et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996;128(4):570-3.
29. Monneret G, Labaune JM, Isaac C, Bienvenu F, Putet G, Bienvenu J. Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr 1997;86(2):209-12.
30. Nylen ES, O'Neill W, Jordan MH, Snider RH, Moore CF, Lewis M et al. Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res 1992;24(9):439-43.
31. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997;40(7):1250-6.